Company Focus
IQVIA INC.
Latest IQVIA INC. News
Pharmaceutical
The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or improving quality. 9 December 2024
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.
Latest News & Features of interest to IQVIA INC.
Biotechnology
UK pharma major AstraZeneca on Friday revealed that Datroway (datopotamab deruxtecan or Dato-DXd) has been approved in the USA. 18 January 2025
Pharmaceutical
Telix Pharmaceuticals has announced a definitive agreement to acquire key assets from ImaginAb, a specialist in antibody engineering. 17 January 2025
Biotechnology
The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech major Amgen, for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. 17 January 2025
Biotechnology
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic obstructive pulmonary disease (COPD) treatment. 17 January 2025
Pharmaceutical
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following concerns regarding an increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION). 17 January 2025
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing that primary and key secondary endpoints were not met. 17 January 2025
Biotechnology
Orna Therapeutics and Shanghai Simnova have announced an expansion of their strategic collaboration to develop RNA-based therapies in multiple myeloma. 17 January 2025
Pharmaceutical
China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), from Innovent Biologics and Aosaikang Pharmaceuticals (ASK Pharm). 17 January 2025
Pharmaceutical
The US Food and Drug Administration has granted AstraZeneca’s Calquence (acalabrutinib) full approval as part of a combination therapy for mantle cell lymphoma (MCL). 17 January 2025
Pharmaceutical
Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with an arsenal of innovative drugs and therapies. 17 January 2025
Latest In Brief for IQVIA INC.
Biotechnology
US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a Bloomberg report. 18 January 2025
Latest Relevant Ones To Watch News
US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech developing small molecule precision oncology therapies. 14 January 2025
13 January 2025
13 January 2025
13 January 2025
11 January 2025
10 January 2025
8 January 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze